David Hellerstein
Professor of Clinical Psychiatry at Columbia University Irving Medical Center; Research Psychiatrist at the New York State Psychiatric Institute; Director of the Depression Evaluation Service
Data updated
Research Footprint
David Hellerstein appears in 6 tracked papers (2022–2026), most studied alongside Psilocybin, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Suicidality.
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: Guy Goodwin, Scott Tyler Aaronson and Robin Carhart-Harris.
Background & Research
David J. Hellerstein, MD, is a research psychiatrist at the New York State Psychiatric Institute and Professor of Clinical Psychiatry at Columbia University Irving Medical Center. He directs Columbia’s Depression Evaluation Service, and his work focuses on mood and anxiety disorders, especially treatment-resistant depression. Since 2019, his group has also taken a leadership role in psychedelic medication studies, including psilocybin for depression and other disorders.
Key Impact
He is a principal investigator on psilocybin studies for treatment-resistant depression and related psychiatric conditions, helping establish the clinical evidence base for psychedelic-assisted therapy.
Collaboration Network
28 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations David Hellerstein is associated with.
Columbia University
academicResearch with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.
View stakeholder →New York State Psychiatric Institute
State-funded psychiatric research institute affiliated with Columbia University, located in New York City. A key site for psilocybin clinical trials including the landmark COMP360 study for treatment-resistant depression, and conducts broader research on LSD, DMT, ayahuasca, and ketamine through Columbia's Depression Evaluation Service.
View stakeholder →COMPASS Pathways
Public BiotechCOMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
View stakeholder →